Kornimate/medical-research-clean huggingface dataset:
tracking of lipid lowering therapy in jordan

Conditions: Dyslipidemias; Atherosclerotic Cardiovascular Disease

Summary: the present study aims to examine the clinical practice of modifying the dose of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ascvd), who have ldl-c \> 70 mg/dl despite statin treatment.

ascvd is the leading cause of morbidity and mortality worldwide, in the middle east and in jordan. one of the major risk factors that contribute to the development and progression of ascad is dyslipidemia. a large number of clinical trials have reported the benefits of lowering ldl-c, in reducing the mortality rate among ascad patients. the 2019 acc/aha blood cholesterol treatment guideline to reduce atherosclerotic cardiovascular risk in adults has expanded the role of ldl-c targets and reiterated the importance of achieving an ldl-c level of 70 mg/dl or less for patients who have ascvd. patients on statins and other lipid-lowering therapy in jordan have not been tracked in the past for the potential of up escalating the lipid-lowering therapy to reach the ldl-c target. the investigation will enroll patients with ascvd who have lal-c \>70 mg/dl on lipid-lowering therapy and follow them for 12 months to examine the treating physicians' action in up-titrating the lipid-lowering therapy dose(s) and the frequency of measuring serum lipids during the study period.

Eligibility criteria:
inclusion criteria 1. adults aged 18 years or old. 2. presence of atherosclerotic cardiovascular disease on lipid-lowering therapy. 3. ldl-c \> 70mg/dl. 4. willingness to sign an informed consent. exclusion criteria 1. life-threatening disease with limited survival. 2. unwillingness to sign an informed consent.

Keywords: low-density lipoprotein cholesterol (ldl-c), target levels
large-scale metabolomic profiling for the diagnosis of inborn errors of metabolism

Conditions: Congenital Disorders of Glycosylation

Summary: researchers are trying to determine the efficacy of a global metabolomic approach in testing for and diagnosing inborn errors of metabolism as opposed to traditional testing methods.

residual samples will be tested for a variety of biomarkers that may lead to better understanding of these disorders and help develop treatment options.

Eligibility criteria:
inclusion criteria: * all individuals with specimens in biochemical genetics laboratory and from patients collected under another irb who have agreed to share samples/data exclusion criteria: * none
screening tool for malnutrition, sarcopenia, and cachexia

Conditions: Malnutrition; Sarcopenia; Cachexia

Summary: there is an accumulating evidence of the overlap and frequent co-occurrence of twasting conditions in older adults. those conditions include malnutrition, sarcopenia, and cachexia, therefore , a tool capable of simultaneously screening for all three conditions is imperative. in this study, we developed and validated a new tool for the simultaneous screening of muscle wasting diseases in older adults. the diagnostic accuracy of the new tool was compared to other validated screening tools including the mini nutritional assessment-short form (mna-sf), the short nutritional assessment questionnaire (snaq), and the simple questionnaire to rapidly diagnose sarcopenia (sarc-f).


Eligibility criteria:
inclusion criteria: * participants aged 65 years and older, who agree to participate exclusion criteria: * patients with critical illness. * patients with severe cognitive, hearing or visual impairment hindering proper communication * patients with physical disability that interfere with physical performance assessment or hand grip measurement * patient with any contraindication of to the use of bia) e.g. presence of a pacemaker, other implanted electrical devices, or metal implants, volume overload

Keywords: screening older adult malnutrition cachexia sarcopenia
efficacy of noisome as a carrier of locally delivered minocycline hydrochloride gel

Conditions: Periodontitis

Summary: the goal of this clinical trial is to compare the efficacy of noisome as carrier of minocycline hydrochloride gel to minocycline hydrochloride in stage ii or stage iii periodontitis . the main questions it aims to answer are: * is the noisome carrier of minocycline hydrochloride has an effect in comparing to minocycline hydrochloride in stage ii or stage iii periodontitis? * what is the release profile of of minocycline hydrochloride noisome gel and minocycline hydrochloride gel? participants will be asked to maintain oral hygiene after application of treatment researchers will compare the effect of noisome as a carrier of locally delivered minocycline hydrochloride gel to minocycline hydrochloride gel in stage ii or stage iii periodontitis patients as an adjunct to non-surgical periodontal treatment\] to see if plaque index (pi) , gingival index,clinical attachment level (cal) \&periodontal pocket depth decreased or not.

this study is designed to be a randomized, controlled, blinded, clinical trial; the eligible participants will be randomly allocated for one of the two comparative parallel-groups; test and control group . the interventions will be prepared by the pharmacist and coded and the whole-time frame for the study will be 18 weeks. the intervention to all participants will be non-surgical debridement the the test group will receive the noisome minocycline hydrochloride \& control group will receive minocycline hydrochloride.

Eligibility criteria:
inclusion criteria: * participants willing to commit for the entire period of the trial and agreed to sign the written consent after full explanation of the study. * generalized periodontitis (stage ii or stage iii ) patients; ( ≥ 3 mm cal, pd 5-7 mm ) , premolar-molar area (test site) . * having more than 16 tooth excluding wisdom and test teeth that still had both mesial and distal neighboring teeth. * systemically free according to the modified burkitt's health history questionnaire exclusion criteria: * non-surgical periodontal therapy within the previous 12 months, systemic or local use of antibiotics with the previous 3 months, medication with possible influence on the periodontium. * pregnancy or contraceptives usage. * breastfeeding. * known allergy to the ingredients of the treatment. * smokers. * vulnerable group; prisoners \& orphans .

Keywords: minocycline hydrochloride
the effects of simulation-based ultrasound training on continuity of care in managing pre-mature onset of labor

Conditions: Continuity of Care

Summary: simulation-based training lead to improvements in learning compared to no intervention but little is known of the effects on organizational improvements that are relevant to patient care. this study focused on the effects of training midwives in performing cervical ultrasound scans on continuity of care when managing pregnant women with symptoms of premature onset of labor. our hypothesis is that simulation-based training can be used to decrease the number of shifts in primary responsible health care practitioner as midwives that are trained in cervical ultrasound scans may manage the patient encounter without engaging a second practitioner (i.e. an obstetrician).

pregnant women with symptoms of premature onset of labor are typically managed by midwives and obstetricians but shifts in responsibility in patient care may result in lack of continuity of care. this may, in turn, result in threats to patient safety and delays in initiation of treatment due to long wait times. this study examined the effects of simulation-based ultrasound training on the management of women with symptoms of pre-mature onset of labor. 12 midwives were randomized to simulation-based ultrasound training focusing on cervical assessment or no training (controls). the midwives in the intervention group were trained to an expert criterion on a high-fidelity transvaginal ultrasound simulator. once this level was attained, they continued clinical training until proficiency in performing cervical scans independently. proficiency was determined using a previously validated assessment instrument (the objective structured assessment of ultrasound skills) and by sending in pictures for the fetal medicine foundation certification programme. the number of responsible health care practitioners providing care for pregnant women with acute onset of symptoms of premature onset of labor is registered along with time from arrival at the hospital to medical assessment and treatment is commenced. differences between patients treated by the two groups of midwives are compared over a period of 6 months. during this period all patients with symptoms of premature onset of labor are included, of which only a small proportion are admitted for further examinations and treatment. the vast majority are expected to be scheduled for ambulatory follow-up.

Eligibility criteria:
inclusion criteria: all midwives who are taking shift on the maternity ward exclusion criteria: any prior ultrasound training and planned maternity leave.
insulin fiasp vs. insulin novorapid during pregnancy and laction in women with pre-existing diabetes

Conditions: Diabetes Mellitus; Pregnancy Complications

Summary: a randomised controlled, open-label trial in an unselected cohort of pregnant women with type 1 or type 2 diabetes allocated to insulin fiasp® or insulin novorapid® during pregnancy and lactation.


Eligibility criteria:
inclusion criteria * women, age ≥ 18 years * duration of type 1 diabetes (or mature onset of diabetes in the young) ≥ 12 months * type 2 diabetes (any duration) * pregnant with an intrauterine singleton living fetus confirmed by an ultrasound scan between 8+0 and 13+6 gestational weeks * routine use of insulin pump therapy, insulin detemir, insulin degludec, insulin glargine, insulin abasaglar, insulin toujeo or neutral protamine hagedorn insulin and willing to continue routine treatment modality * women with type 1 diabetes using an insulin pump compatible with trial products * women with type 2 diabetes treated with diet, oral antidiabetic therapy or pre-mixed insulin before pregnancy and willing to change to trial medication according to randomization or to an appropriate long-acting insulin analogue, as indicated * proficiency in danish to understand oral and written information exclusion criteria • severe mental or psychiatric barriers or concurrent disease on the decision of the principal investigator
enhanced tb screening to determine the prevalence and incidence of tb in patients with hiv

Conditions: Tuberculosis

Summary: this study will examine an enhanced protocol to systematically screen a cohort of 400 new hiv clinic enrollees for prevalence and 1-year incidence of tuberculosis (tb).

zambia is a high burden country for both hiv and tb infection and hiv clinic enrollees are a high-risk group for active tb. current zambian ministry of health screening protocols are symptom-based even though active case-finding studies in hiv-infected populations have shown that symptoms are not always predictive of active tb. as a result, there may be a significant amount of un-diagnosed tb among hiv-infected zambians even in the context of accessing hiv care. this study will examine an enhanced protocol to systematically screen a cohort of 400 new hiv clinic enrollees for prevalence and 1-year incidence of tb using symptoms, light and fluorescence microscopy, chest radiography and tb culture of sputum and extra-pulmonary fluids (when indicated). in addition, the sensitivity, specificity and cost-effectiveness of each diagnostic tool will be evaluated.

Eligibility criteria:
inclusion criteria: * persons with hiv/aids, 16 years of age or older, who are enrolling at the kalingalinga art clinic and are able and willing to provide informed consent * antiretroviral therapy-naïve except for short-course therapy through prevention of mother-to-child-transmission programs * not have taken any tb treatment in the past 3 months * willing to provide locator information and allow study staff to contact by phone or visit them at home if required exclusion criteria: * any condition, including active drug or alcohol use, which in the opinion of the investigators, would interfere with adherence to study requirements

Keywords: tb hiv extensively resistant tb extra pulmonary tb
death rate in anesthesia, a study in a tertiary hospital

Conditions: Sudden Death

Summary: death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. in this study, the investigators will follow the death among patients who underwent surgery under anesthesia whether regional or general over the next two years from 2016 to 2018.

death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. most of the studies of death rate in anesthesia are retrospective with many drawbacks and pitfalls like absence of information in the records of the patients. in this study, the investigators will follow the death among patients who underwent surgery under anesthesia whether regional or general over the next two years from 2016 to 2018, by examining the patients records from the hospital database and recording the events that occur to the dead patients. the end point of this study will be anesthesia death rate inside the hospital.

Eligibility criteria:
inclusion criteria: * patients who underwent anesthesia and surgery. * patients who died inside the hospital. exclusion criteria: * patient who underwent anesthesia and surgery and do not died and discharged home. * patients who died outside the hospital.

Keywords: anesthesia
effects of dry needling on neck and shoulder pain in orchestral musicians: a prospective case series

Conditions: Pain Syndrome; Musculoskeletal Pain; Trigger Point Pain, Myofascial

Summary: this study evaluates the effectiveness of deep dry needling of active myofascial trigger points present in muscles of the neck and shoulder region in orchestral musicians.


Eligibility criteria:
inclusion criteria: * orchestral musicians * chronic neck or shoulder pain * presence of active myofascial trigger points exclusion criteria: * fear of needles * coagulation disorders * pregnancy
nitrocamptothecin in treating patients with recurrent or metastatic ovarian epithelial or primary peritoneal cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of nitrocamptothecin in treating patients who have recurrent or metastatic ovarian epithelial or primary peritoneal cancer.

objectives: * determine the antitumor activity of nitrocamptothecin in patients with recurrent or metastatic ovarian epithelial or primary peritoneal cancer. * determine the nature and degree of toxicity of this regimen in these patients. outline: patients receive oral nitrocamptothecin on days 1-5. treatment continues every 7 days in the absence of disease progression or unacceptable toxicity. patients are followed at 2 weeks, then every 3 months for 2 years, and then every 6 months for 3 years. projected accrual: approximately 19-51 patients will be accrued for this study within 22 months.

Eligibility criteria:
disease characteristics: * histologically confirmed recurrent or metastatic ovarian epithelial or primary peritoneal cancer * measurable disease * ascites and pleural effusions are not considered measurable * sonography allowed if bidimensionally measurable * must not be eligible for higher priority gog protocol patient characteristics: age: * not specified performance status: * gog 0-2 life expectancy: * not specified hematopoietic: * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 * granulocyte count at least 1,500/mm\^3 hepatic: * bilirubin no greater than 1.5 times upper limit of normal (uln) * sgot and alkaline phosphatase no greater than 3 times uln renal: * creatinine no greater than 2.0 mg/dl other: * no other prior or concurrent invasive malignancy in the past 5 years except nonmelanoma skin cancer * no active infection prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least but no more than 2 prior chemotherapy regimens containing carboplatin, cisplatin, or another organoplatinum compound combined with paclitaxel * second line therapy may include any agents except topoisomerase i inhibitors (i.e., topotecan) * no prior nitrocamptothecin or topoisomerase i inhibitors * at least 3 weeks since prior chemotherapy and recovered endocrine therapy: * not specified radiotherapy: * at least 3 weeks since prior radiotherapy and recovered surgery: * at least 3 weeks since prior surgery and recovered other: * no prior cancer therapy that contraindicates this study

Keywords: stage iv ovarian epithelial cancer recurrent ovarian epithelial cancer primary peritoneal cavity cancer
decitabine followed by donor lymphocyte infusion for patients with relapsed acute myeloblastic leukemia(aml) after allogeneic stem cell transplantation

Conditions: Recurrent Adult Acute Myeloid Leukemia

Summary: decitabine can up-regulate a series of immune associated proteins, including cancer testis antigens (cta), major histocompatibility complex (mhc), co-stimulatory molecules and adhesion molecules, which suggests a potential benefit for a following adoptive t cell therapy. in addition, decitabine induce foxp3 expression in cd4+ t cells and convert cd4+ t cells into t regulatory cells(tregs). as a result, graft versus host disease(gvhd) can be reduced by treatment of decitabine.


Eligibility criteria:
inclusion criteria: * age 18 - 60 years * histologically or cytologically documented relapse of acute myeloid leukemia after a stem cell transplant * must have the ability to observe the efficacy and events * patient must have ability to understand and willingness to provide written informed consent prior to participation in the study and any related procedures being performed * must have an eastern cooperative oncology group (ecog) performance status =\< 3 * must have suitable donor exclusion criteria: * must not have an advanced malignant hepatic tumor * must not receive any other forms of chemotherapy after cell infusion during the treatment protocol * must not be receiving any other investigational agents within 14 days of first dose of study drug * must not have uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements * must not be pregnant or breastfeeding; pregnant women are excluded from this study because decitabine is a category d agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with decitabine, breastfeeding should be discontinued if the mother is treated with decitabine; these potential risks may also apply to other agents used in this study * must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study * must not have a known or suspected hypersensitivity to decitabine * must not be human immunodeficiency virus (hiv)-positive and on combination antiretroviral therapy; these patients are ineligible because of the potential for pharmacokinetic interactions with decitabine; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Keywords: demethylating agent immunogenicity decitabine(dac) donor lymphocyte infusion(dli) aml
stoma closure and reinforcement trial ll

Conditions: Ileostomy - Stoma; Inflammatory Bowel Diseases

Summary: hernia formation at sites of ostomy closure is a common complication. the investigator believes that using evidence based hernia repair techniques as a preventive measure during closure of ostomies will reduce the incidence of hernia formation. in this trial, the investigator will pilot a novel technique of monofilament bioresorbable mesh reinforcement of the abdominal wall defects that remain after closure of an ileostomy to evaluate for safety and begin to evaluate the effectiveness compared to standard techniques.


Eligibility criteria:
inclusion criteria: 1. age \> 18years. 2. patient is undergoing closure of loop ileostomy. 3. patient has a diagnosis of inflammatory bowel disease treated with resection and diverting loop ileostomy. 4. patient has been evaluated by a qualified surgeon and found to be a suitable candidate for surgery. exclusion criteria: 1. pre-existing systemic infection at the time of ileostomy takedown 2. cirrhosis, chronic renal failure requiring dialysis, or collagen disorder 3. previous abdominal hernia repair with mesh placement 4. concurrent surgical procedures in addition to closure of diverting loop ileostomy 5. ileostomy closure not completed through the previous stoma site (i.e. those requiring exploratory laparotomy for closure)

Keywords: ileostomy hernia inflammatory bowel disease ibd
laser ablation study for treatment of atrial fibrillation (laser)

Conditions: Atrial Fibrillation

Summary: this protocol aims at assessing the efficacy of performing catheter ablation for atrial fibrillation (af) with laser catheters versus performing it with radiofrequency (rf) catheters. in order to study laser catheter ablation efficacy, mri analysis of the lesions 3 months after the procedure will be performed in both groups. mri analysis will detect ablation gaps in the lesions encircling pulmonary veins. the primary endpoint will compare the number of gaps in the laser catheter and the rf group. the secondary endpoint of the study is recurrence of af after 12 months. the target population of the study is patients with paroxysmal or persistent af undergoing af ablation.


Eligibility criteria:
inclusion criteria: * patients with clinical recurrent af, refractary or intolerant to at least 1 antiarrhythmic drub who are scheduled to undergo ablation of pulmonary veins (pv) * signed consent form. exclusion criteria: * being under 18 years old * any contraindication for ablation procedure * impossibility to acquire de-mri because of contraindication (e.g. severely impaired renal function) or patient unwillingness

Keywords: catheter ablation radiofrequency laser atrial fibrillation
therapeutic strategies in sexual function

Conditions: Male Sexual Dysfunction; Spinal Cord Injury

Summary: objectives: to know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions.

methods: this is a descriptive observational study involving 24 men with a mean age of 32.62 (ci 28.65 to 36.60), with spinal cord injury, recruited in reference services in spinal cord injury recife (pe). the subjects underwent neurological evaluation in accordance with the guidelines of the international standards for neurological examination and functional classification of spinal cord injury (isncsci), the american spinal injury association (asia), assessment of sexual function through the erectile function of international index (iief) and answered a semi-structured form to identify therapeutic strategies used in sexual function. to collect information about medicinal plants, a search was made in the surroundings of public markets located in the metropolitan region of recife (pe).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of traumatic spinal cord injury * injury time less than six months * heterosexual * sexually active exclusion criteria: * patients who had erectile dysfunction attributed to endocrine or metabolic disease order * those who underwent surgery in the genital area, such as radical prostatectomy or penile implant * cognitive impairment

Keywords: sexuality spinal cord injuries complementary therapies medicinal plants